Life Science News

2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter

Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.

"This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "Veklury is making a significant impact as the COVID-19 pandemic continues to evolve. The dynamics of the HIV treatment market further improved and this contributed to record Biktarvy revenue. In oncology, our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, the approval of Tecartus in relapsed or refractory acute lymphoblastic leukemia and two new trial starts for magrolimab in solid tumors."

Third Quarter 2021 Financial Results

  • Total third quarter 2021 revenue of $7.4 billion increased 13% compared to the same period in 2020, due to increased demand for Veklury ® (remdesivir 100 mg for injection).
  • Diluted Earnings Per Share ("EPS") increased to $2.05 for the third quarter 2021 compared to $0.29 for the same period in 2020. The increase was primarily driven by lower acquired in-process research and development ("IPR&D") expenses, higher net sales and lower unrealized losses from our equity securities.
  • Non-GAAP diluted EPS increased 26% to $2.65 for the third quarter 2021 compared to $2.11 for the same period in 2020, primarily due to higher operating income, partially offset by lower interest income.
  • As of September 30, 2021, Gilead had $6.8 billion of cash, cash equivalents and marketable debt securities compared to $7.9 billion as of December 31, 2020.
  • During the third quarter 2021, Gilead generated $3.3 billion in operating cash flow.
  • During the third quarter 2021, Gilead made $2.5 billion in debt repayments, paid cash dividends of $900 million and utilized $145 million to repurchase common stock.

Product Sales Performance

Total third quarter 2021 product sales increased 13% to $7.4 billion compared to the same period in 2020. Total product sales excluding Veklury decreased 3% to $5.4 billion for the third quarter 2021 compared to the same period in 2020, primarily reflecting the expected loss of exclusivity of Truvada ® (emtricitabine ("FTC") 200 mg/tenofovir disoproxil fumarate 300 mg ("TDF")) and Atripla ® (efavirenz 600 mg/FTC 200 mg/TDF 300mg) in the United States, partially offset by continued increased demand for Biktarvy ® (bictegravir 50 mg/FTC 200 mg/tenofovir alafenamide 25 mg ("TAF")) and Trodelvy ® (sacituzumab govitecan-hziy).

HIV product sales decreased 8% to $4.2 billion for the third quarter 2021 compared to the same period in 2020, reflecting, as expected, the loss of exclusivity of Truvada and Atripla in the United States, as well as lower channel inventory as compared to the same period in 2020, primarily driven by pandemic-related stocking in the prior year, partially offset by higher Biktarvy demand and improved trends in the treatment market.

  • Biktarvy sales increased 20% year-over-year in the third quarter 2021, reflecting higher treatment demand and net price.
  • Descovy ® (FTC 200 mg/TAF 25 mg) sales decreased 15% year-over-year in the third quarter 2021, primarily driven by lower net price.
  • Truvada and Atripla sales decreased 87% and 76% year-over-year, respectively, in the third quarter 2021, as expected, due to the loss of exclusivity in the United States in late 2020.

Hepatitis C virus ("HCV") product sales decreased 8% to $429 million for the third quarter 2021 compared to the same period in 2020, primarily driven by a favorable settlement in the same period 2020 that did not repeat, fewer patient starts outside the United States, and timing of Department of Corrections purchases on a relative basis.

Hepatitis B virus ("HBV") and hepatitis delta virus ("HDV") product sales increased 17% to $247 million for the third quarter 2021 compared to the same period in 2020. Vemlidy ® (TAF 25 mg) sales increased 18% in the third quarter 2021 compared to the same period in 2020, driven primarily by uptake in geographies outside the United States. Hepcludex ® (bulevirtide) contributed $12 million in the third quarter 2021 as launch activities continued across Europe.

Cell Therapy product sales increased 51% to $222 million for the third quarter 2021 compared to the same period in 2020.

  • Yescarta ® (axicabtagene ciloleucel) sales increased to $175 million in the third quarter 2021, driven by continued demand in relapsed or refractory large B-cell lymphoma ("LBCL") and strong uptake in relapsed or refractory indolent follicular lymphoma in the United States and Europe.
  • Tecartus ® (brexucabtagene autoleucel) sales were $47 million for the third quarter 2021, driven by increased adoption in mantle cell lymphoma in the United States and Europe.

Trodelvy sales for the third quarter 2021 were $101 million, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer ("TNBC") and metastatic urothelial cancer in the United States.

Veklury sales were $1.9 billion for the third quarter 2021. Sales of Veklury are generally affected by COVID-19 related rates of infections, hospitalizations and vaccinations.

Third Quarter 2021 Product Gross Margin, Operating Expenses and Tax

  • Product gross margin was 83.4% for the third quarter 2021 compared to 82.4% in the same period in 2020, driven by the reversal of a previously recorded $175 million litigation reserve following a favorable court decision, as well as lower royalty expense and change in product mix, partially offset by higher amortization of intangibles acquired from Immunomedics, Inc. and MYR GmbH ("MYR"). Non-GAAP product gross margin was 90.0% for the third quarter 2021 compared to 86.5% in the same period in 2020, driven by the reversal of the aforementioned previously recorded litigation reserve following a favorable court decision, as well as lower royalty expense and change in product mix.
  • Research and Development ("R&D") expenses and non-GAAP R&D expenses for the third quarter 2021 were $1.1 billion compared to $1.2 billion in the same period in 2020. Lower R&D expenses reflect completion or wind-down of remdesivir and inflammation related clinical programs, partially offset by increases in Trodelvy and magrolimab clinical activities.
  • Selling, General and Administrative ("SG&A") expenses and non-GAAP SG&A expenses for the third quarter 2021 were $1.2 billion compared to $1.1 billion in the same period in 2020. The increase in SG&A expenses was driven by increased promotional and marketing activities across all geographies, primarily for Trodelvy.
  • The GAAP effective tax rate ("ETR") and non-GAAP ETR for the third quarter 2021 were 24.8% and 18.9%, respectively, compared to 57.2 % and 18.4%, respectively, for the same period in 2020.

Key Updates Since Our Last Quarterly Release

Viral Diseases

  • Presented positive results at the IDWeek conference from the Phase 3 double-blind, placebo-controlled trial (PINETREE) of Veklury administered intravenously in non-hospitalized COVID-19 patients at high risk for disease progression. Results demonstrated statistically significant reduction in risk for COVID-19 related hospitalization with Veklury compared with placebo.
  • Received Priority Review designations from FDA for the lenacapavir New Drug Applications ("NDAs") for the treatment of HIV-1 infection in heavily treatment-experienced patients with multidrug resistance in combination with other antiretroviral agents. The NDAs have been granted a Prescription Drug User Fee Act action date of February 28, 2022.
  • Announced that the Marketing Authorization Application ("MAA") for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, was fully validated by European Medicines Agency ("EMA"). The proposed indication is for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multidrug resistant HIV-1 infection who are currently on a failing antiretroviral treatment regimen due to resistance, intolerance or safety considerations.
  • Announced the initiation of the Phase 2 study evaluating an oral weekly combination of lenacapavir and islatravir in people who are living with HIV who are virologically suppressed on an antiretroviral therapy.
  • Began enrollment into the Phase 3 PURPOSE 1 trial in cisgender girls and young women, the second Phase 3 study of lenacapavir for HIV pre-exposure prophylaxis. The first Phase 3 study (PURPOSE 2) was initiated in July and is enrolling cisgender men, transgender men and women, and gender non-binary individuals who have sex with men.
  • Received FDA approval for the supplemental NDA of a new low-dose tablet form of Biktarvy (bictegravir 30mg/FTC 120mg/TAF 15mg), expanding the indication to include younger children weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. Biktarvy (bictegravir 50mg/FTC 200mg/TAF 25mg) is approved for appropriate pediatric patients weighing at least 25 kg.

Oncology

  • Announced the inclusion of Trodelvy into the National Comprehensive Cancer Network Guidelines for Breast Cancer as a preferred regimen for the treatment of adult patients with metastatic TNBC who received at least two prior therapies, with at least one for metastatic disease.
  • Received a positive opinion from the Committee for Medicinal Products for Human Use of the EMA for Trodelvy for the treatment of adults with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The final European Commission decision is anticipated later in 2021.
  • Received approval from Health Canada for Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior therapies, at least one of them for metastatic disease. Canada represents the fifth approval for Trodelvy in metastatic TNBC under the Project Orbis Initiative, following approvals in Australia, Great Britain, Switzerland, and the United States.
  • Presented sub-analyses data from the Phase 3 ASCENT study evaluating Trodelvy in patients with relapsed or refractory metastatic TNBC at the European Society of Medical Oncology annual meeting. Results showed significant and clinically-meaningful improvements in health-related quality of life, and, in patients whose initial diagnosis was not TNBC but changed to triple-negative, Trodelvy demonstrated similar positive outcomes to the overall metastatic TNBC population.
  • Announced the submission of a supplemental Biologics License Application to FDA for Yescarta to expand its current indication to include the treatment of adults with relapsed or refractory LBCL in the second-line setting.
  • Received FDA approval for Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
  • Announced a collaboration and license agreement with Appia Bio, Inc. to research and develop hematopoietic stem cells-derived cell therapies directed toward hematological malignancies.

Corporate

  • Announced that the company's Board of Directors has declared a quarterly dividend of $0.71 per share of common stock for the fourth quarter of 2021. The dividend is payable on December 30, 2021, to stockholders of record at the close of business on December 15, 2021. Future dividends will be subject to Board approval.
  • Announced donation of 100,000 vials of Veklury to Indonesia and 3,000 vials to Armenia to help patients hospitalized with COVID-19.

Guidance and Outlook

Gilead has updated its full-year guidance, and now expects:

  • Total product sales between $26.0 billion and $26.3 billion, compared to $24.4 billion and $25.0 billion previously, reflecting year-to-date results and our updated expectations for the fourth quarter 2021.
  • Total product sales, excluding Veklury, of approximately $21.5 billion, compared to $21.7 billion and $21.9 billion previously, primarily reflecting the longer than expected pandemic impact on our business.
  • Total Veklury sales between $4.5 billion and $4.8 billion, compared to $2.7 billion and $3.1 billion previously, primarily reflecting the surge in COVID-19 hospitalizations in the third quarter 2021, and our expectations for a significant step-down in hospitalization rates in the fourth quarter 2021.
  • GAAP earnings per share between $5.50 and $5.70, compared to $4.70 and $5.05 previously.
  • Non-GAAP earnings per share between $7.90 and $8.10, compared to $6.90 and $7.25 previously.

A reconciliation between GAAP and non-GAAP financial information for the 2021 guidance is provided in the accompanying tables. Also see the Forward-Looking Statements described below. The financial guidance is subject to a number of risks and uncertainties, including uncertainty around the duration and magnitude of the COVID-19 pandemic. While the pandemic can be expected to continue to impact Gilead's business and broader market dynamics, the rate and degree of these impacts as well as the corresponding recovery from the pandemic may vary across Gilead's business.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges, acquired IPR&D expenses, and other items that are considered unusual or not representative of underlying trends of Gilead's business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Acquired IPR&D expenses reflect IPR&D impairments as well as the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and other payments related to various collaborations and the initial costs of rights to IPR&D projects. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead's results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales, Gilead's ability to recoup the expenses incurred to date and future expenses related to the development and production of Veklury, and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2021 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its antiviral and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including those involving Appia Bio, Inc.; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy and Veklury; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, including FDA approval of lenacapavir for treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant infection, EMA approval of lenacapavir for treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multidrug resistant HIV-1 infection who are currently on a failing antiretroviral treatment regimen due to resistance, intolerance or safety considerations, EMA approval of Trodelvy for the treatment of adults with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease, and FDA approval of Yescarta for treatment of adults with relapsed or refractory LBCL in the second-line setting, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2021 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD ® , GILEAD SCIENCES ® , AMBISOME ® , ATRIPLA ® , BIKTARVY ® , CAYSTON ® , COMPLERA ® , DESCOVY ® , DESCOVY FOR PREP ® , EMTRIVA ® , EPCLUSA ® , EVIPLERA ® , GENVOYA ® , HARVONI ® , HEPCLUDEX ® (BULEVIRTIDE), HEPSERA ® , JYSELECA ® , LETAIRIS ® , ODEFSEY ® , RANEXA ® , SOVALDI ® , STRIBILD ® , TECARTUS ® , TRODELVY ® , TRUVADA ® , TRUVADA FOR PREP ® , TYBOST ® , VEKLURY ® , VEMLIDY ® , VIREAD ® , VOSEVI ® , YESCARTA ® and ZYDELIG ® . This report may also refer to trademarks, service marks and trade names of other companies.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions, except per share amounts)

2021

2020

2021

2020

Revenues:

Product sales

$

7,356

$

6,493

$

19,848

$

17,027

Royalty, contract and other revenues

65

84

213

241

Total revenues

7,421

6,577

20,061

17,268

Costs and expenses:

Cost of goods sold

1,223

1,141

3,974

3,174

Research and development expenses

1,147

1,158

3,336

3,461

Acquired in-process research and development expenses

19

1,171

177

5,792

Selling, general and administrative expenses

1,190

1,106

3,596

3,421

Total costs and expenses

3,579

4,576

11,083

15,848

Income from operations

3,842

2,001

8,978

1,420

Interest expense

(250)

(236)

(763)

(717)

Other income (expense), net

(154)

(940)

(696)

(848)

Income (loss) before income taxes

3,438

825

7,519

(145)

Income tax expense

(852)

(472)

(1,694)

(1,310)

Net income (loss)

2,586

353

5,825

(1,455)

Net loss attributable to noncontrolling interest

6

7

18

27

Net income (loss) attributable to Gilead

$

2,592

$

360

$

5,843

$

(1,428)

Net income (loss) per share attributable to Gilead common stockholders - basic

$

2.06

$

0.29

$

4.65

$

(1.14)

Shares used in per share calculation - basic

1,256

1,255

1,256

1,257

Net income (loss) per share attributable to Gilead common stockholders - diluted

$

2.05

$

0.29

$

4.63

$

(1.14)

Shares used in per share calculation - diluted

1,262

1,261

1,262

1,257

Cash dividends declared per share

$

0.71

$

0.68

$

2.13

$

2.04

GILEAD SCIENCES, INC.

TOTAL REVENUE SUMMARY

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In millions, except percentages)

2021

2020

Change

2021

2020

Change

Product sales:

HIV

$

4,189

$

4,547

(8)%

$

11,777

$

12,681

(7)%

HCV

429

464

(8)%

1,488

1,641

(9)%

HBV/HDV (1)

247

211

17%

704

616

14%

Cell Therapy

222

147

51%

632

444

42%

Trodelvy

101

NM

262

NM

Other

245

251

(2)%

777

772

1%

Total product sales excluding Veklury

5,433

5,620

(3)%

15,640

16,154

(3)%

Veklury

1,923

873

NM

4,208

873

NM

Total product sales

7,356

6,493

13%

19,848

17,027

17%

Royalty, contract and other revenues

65

84

(23)%

213

241

(12)%

Total revenues

$

7,421

$

6,577

13%

$

20,061

$

17,268

16%

_______________________________

NM - Not Meaningful

(1) The nine months ended September 30, 2021 includes $25 million of Hepcludex sales recorded subsequent to Gilead's acquisition of MYR.

GILEAD SCIENCES, INC.

NON-GAAP FINANCIAL INFORMATION (1)

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In millions, except percentages)

2021

2020

Change

2021

2020

Change

Non-GAAP:

Cost of goods sold

$

736

$

875

(16)%

$

2,427

$

2,376

2%

Research and development expenses

$

1,109

$

1,155

(4)%

$

3,242

$

3,345

(3)%

Acquired in-process research and development expenses

$

19

$

NM

$

19

$

NM

Selling, general and administrative expenses

$

1,178

$

1,095

8%

$

3,332

$

3,335

—%

Other income (expense), net

$

(12)

$

29

NM

$

(29)

$

203

NM

Diluted EPS

$

2.65

$

2.11

26%

$

6.60

$

4.90

35%

Product gross margin

90.0

%

86.5

%

350 bps

87.8

%

86.0

%

180 bps

Research and development expenses as a % of revenues

14.9

%

17.6

%

-270 bps

16.2

%

19.4

%

-320 bps

Selling, general and administrative expenses as a % of revenues

15.9

%

16.6

%

-70 bps

16.6

%

19.3

%

-270 bps

Operating expenses as a % of revenues

31.1

%

34.2

%

-310 bps

32.9

%

38.7

%

-580 bps

Operating margin

59.0

%

52.5

%

650 bps

55.0

%

47.6

%

740 bps

Effective tax rate

18.9

%

18.4

%

50 bps

19.0

%

19.9

%

-90 bps

________________________________

NM - Not Meaningful

(1) A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10 - 11.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions, except percentages and per share amounts)

2021

2020

2021

2020

Cost of goods sold reconciliation:

GAAP cost of goods sold

$

1,223

$

1,141

$

3,974

$

3,174

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

(487)

(266)

(1,547)

(798)

Non-GAAP cost of goods sold

$

736

$

875

$

2,427

$

2,376

Product gross margin reconciliation:

GAAP product gross margin

83.4

%

82.4

%

80.0

%

81.4

%

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

6.6

%

4.1

%

7.8

%

4.7

%

Non-GAAP product gross margin (1)

90.0

%

86.5

%

87.8

%

86.0

%

Research and development expenses reconciliation:

GAAP research and development expenses

$

1,147

$

1,158

$

3,336

$

3,461

Acquisition-related – amortization of inventory step-up charges

(67)

.

(67)

Acquisition-related and other costs (2)

.

29

.

(3)

(27)

(116)

Non-GAAP research and development expenses

$

1,109

$

1,155

$

3,242

$

3,345

Acquired IPR&D expenses reconciliation:

GAAP acquired IPR&D expenses

$

19

$

1,171

$

177

$

5,792

Acquired IPR&D expenses

(1,171)

(158)

(5,792)

Non-GAAP acquired IPR&D expenses

$

19

$

$

19

$

Selling, general and administrative expenses reconciliation:

GAAP selling, general and administrative expenses

$

1,190

$

1,106

$

3,596

$

3,421

Acquisition-related and other costs (2)(3)

(12)

.

(11)

(264)

(86)

Non-GAAP selling, general and administrative expenses

$

1,178

$

1,095

$

3,332

$

3,335

Operating income reconciliation:

GAAP operating income

$

3,842

$

2,001

$

8,978

$

1,420

Acquired IPR&D expenses

1,171

158

5,792

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

554

266

1,614

798

Acquisition-related and other costs (2)(3)

(17)

.

14

291

202

Non-GAAP operating income

$

4,379

$

3,452

$

11,041

$

8,212

Operating margin reconciliation:

GAAP operating margin

51.8

%

30.4

%

44.8

%

8.2

%

Acquired IPR&D expenses

%

17.8

%

0.8

%

33.5

%

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

7.5

%

4.0

%

8.0

%

4.6

%

Acquisition-related and other costs (2)(3)

(0.2)

%

0.2

%

1.4

%

1.2

%

Non-GAAP operating margin (1)

59.0

%

52.5

%

55.0

%

47.6

%

Other income (expense), net reconciliation:

GAAP other income (expense), net

$

(154)

$

(940)

$

(696)

$

(848)

Loss from equity securities, net

142

969

667

1,051

Non-GAAP other income (expense), net

$

(12)

$

29

$

(29)

$

203

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions, except percentages and per share amounts)

2021

2020

2021

2020

Effective tax rate reconciliation:

GAAP effective tax rate

24.8

%

57.2 %

22.5

%

(903.4)

%

Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments (4)

(5.9)

%

(38.8)

%

(3.5)

%

923.3

%

Non-GAAP effective tax rate (1)

18.9

%

18.4

%

19.0

%

19.9

%

Net income attributable to Gilead reconciliation (after tax):

GAAP net income (loss) attributable to Gilead

$

2,592

$

360

$

5,843

$

(1,428)

Acquired IPR&D expenses

1,033

125

5,622

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

446

225

1,301

673

Acquisition-related and other costs (2)(3)

(14)

.

11

189

157

Loss from equity securities, net

154

983

687

1,090

Discrete and related tax charges (4)

165

45

179

82

Non-GAAP net income attributable to Gilead

$

3,343

$

2,657

$

8,324

$

6,196

Diluted EPS reconciliation:

GAAP diluted earnings (loss) per share

$

2.05

$

0.29

$

4.63

$

(1.14)

Acquired IPR&D expenses

0.82

0.10

4.45

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

0.35

0.18

1.03

0.53

Acquisition-related and other costs (2)(3)

0.01

0.16

0.13

Loss from equity securities, net

0.12

0.78

0.54

0.86

Discrete and related tax charges (4)

0.13

0.04

0.14

0.06

Non-GAAP diluted EPS (1)

$

2.65

$

2.11

$

6.60

$

4.90

Non-GAAP adjustment summary:

Cost of goods sold adjustments

$

487

$

266

$

1,547

$

798

Research and development expenses adjustments

38

3

94

116

Acquired IPR&D expenses adjustments

1,171

158

5,792

Selling, general and administrative expenses adjustments

12

11

264

86

Total non-GAAP adjustments before other income (expense), net, and income taxes

537

1,451

2,063

6,792

Other income (expense), net, adjustments

142

969

667

1,051

Total non-GAAP adjustments before income taxes

679

2,420

2,730

7,843

Income tax effect of non-GAAP adjustments above

(93)

(168)

(428)

(301)

Discrete and related tax charges (4)

165

45

179

82

Total non-GAAP adjustments after tax

$

751

$

2,297

$

2,481

$

7,624

______________________________

(1) Amounts may not sum due to rounding.

(2) Primarily includes employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's acquisitions of Immunomedics, Inc., Forty Seven, Inc. and MYR.

(3) Includes a donation of equity securities to the Gilead Foundation, a California nonprofit organization, during the second quarter of 2021.

(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2021 FULL YEAR GUIDANCE (1)

(unaudited)

(in millions, except percentages and per share amounts)

Provided

February 4, 2021

Updated

April 29, 2021

Updated

July 29, 2021

Updated

October 28, 2021

Projected product sales GAAP to non-GAAP reconciliation:

GAAP projected product sales

$23,700 - $25,100

Unchanged

$24,400 - $25,000

$26,000 - $26,300

Less: Veklury sales

2,000 - 3,000

2,700 - 3,100

4,500 - 4,800

Non-GAAP projected product sales excluding Veklury sales

$21,700 - $22,100

$21,700 - $21,900

~ $21,500

Projected product gross margin GAAP to non-GAAP reconciliation:

GAAP projected product gross margin

78% - 79%

Unchanged

77% - 78%

~ 79%

Acquisition-related expenses

9%

9%

8%

Non-GAAP projected product gross margin

87% - 88%

86% - 87%

~ 87%

Projected operating income GAAP to non-GAAP reconciliation:

GAAP projected operating income

$9,300 - $10,700

$9,000 - $10,400

$9,200 - $9,900

$10,900 - $11,200

Acquisition-related, acquired IPR&D and other expenses

2,200

2,500

2,700

2,700

Non-GAAP projected operating income

$11,500 - $12,900

$11,500 - $12,900

$11,900 - $12,600

$13,600 - $13,900

Projected effective tax rate GAAP to non-GAAP reconciliation:

GAAP projected effective tax rate

~ 23%

Unchanged

Unchanged

~ 25%

Less: Income tax effect of non-GAAP adjustments and discrete and related tax adjustments

2%

4%

Non-GAAP projected effective tax rate

~ 21%

~ 21%

Projected diluted EPS GAAP to non-GAAP reconciliation:

GAAP projected diluted EPS

$5.25 - $5.95

$4.75 - $5.45

$4.70 - $5.05

$5.50 - $5.70

Acquisition-related, acquired IPR&D and other expenses, historical fair value adjustments of equity securities, related tax effects as well as discrete and related tax adjustments

1.50

2.00

2.20

2.40

Non-GAAP projected diluted EPS

$6.75 - $7.45

$6.75 - $7.45

$6.90 - $7.25

$7.90 - $8.10

________________________________

(1) The 2021 guidance non-GAAP financial information excludes the impact of any potential future acquisition-related, acquired IPR&D and other expenses, fair value adjustments of equity securities and discrete tax and related charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts.

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

September 30,

December 31,

(in millions)

2021

2020

Assets

Cash, cash equivalents and marketable securities

$

6,837

$

7,910

Accounts receivable, net

4,566

4,892

Inventories

2,797

3,014

Property, plant and equipment, net

5,037

4,967

Intangible assets, net

33,900

33,126

Goodwill

8,332

8,108

Other assets

5,629

6,390

Total assets

$

67,098

$

68,407

Liabilities and Stockholders' Equity

Current liabilities

$

10,245

$

11,397

Long-term liabilities

35,382

38,789

Stockholders' equity (1)

21,471

18,221

Total liabilities and stockholders' equity

$

67,098

$

68,407

________________________________

(1) As of September 30, 2021 and December 31, 2020, there were 1,255 and 1,254 shares of common stock issued and outstanding, respectively.

GILEAD SCIENCES, INC.

SELECTED CASH FLOW INFORMATION

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2021

2020

2021

2020

Net cash provided by operating activities

$

3,253

$

2,250

$

8,179

$

6,252

Net cash used in investing activities

(234)

(271)

(2,853)

(5,638)

Net cash provided by (used in) financing activities

(3,527)

4,124

(6,935)

639

Effect of exchange rate changes on cash and cash equivalents

(23)

37

(26)

2

Net change in cash and cash equivalents

(531)

6,140

(1,635)

1,255

Cash and cash equivalents at beginning of period

4,893

6,746

5,997

11,631

Cash and cash equivalents at end of period

$

4,362

$

12,886

$

4,362

$

12,886

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2021

2020

2021

2020

Net cash provided by operating activities

$

3,253

$

2,250

$

8,179

$

6,252

Capital expenditures

(139)

(155)

(423)

(469)

Free cash flow

$

3,114

$

2,095

$

7,756

$

5,783

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2021

2020

2021

2020

HIV Products

Descovy (FTC/TAF) Based Products

Biktarvy – U.S.

$

1,875

$

1,584

$

4,926

$

4,346

Biktarvy – Europe

254

194

707

528

Biktarvy – Other International

147

113

461

314

2,276

1,891

6,094

5,188

Descovy – U.S.

355

424

994

1,124

Descovy – Europe

42

49

128

156

Descovy – Other International

36

35

105

103

433

508

1,227

1,383

Genvoya – U.S.

576

669

1,633

1,927

Genvoya – Europe

100

116

306

376

Genvoya – Other International

68

61

184

183

744

846

2,123

2,486

Odefsey – U.S.

275

309

773

851

Odefsey – Europe

112

116

336

341

Odefsey – Other International

12

12

39

36

399

437

1,148

1,228

Revenue share – Symtuza (1) – U.S.

86

82

261

244

Revenue share – Symtuza (1) – Europe

41

34

125

112

Revenue share – Symtuza (1) – Other International

3

2

8

6

130

118

394

362

Total Descovy (FTC/TAF) Based Products – U.S.

3,167

3,068

8,587

8,492

Total Descovy (FTC/TAF) Based Products – Europe

549

509

1,602

1,513

Total Descovy (FTC/TAF) Based Products – Other International

266

223

797

642

3,982

3,800

10,986

10,647

Truvada (FTC/TDF) Based Products

Atripla – U.S.

21

99

96

275

Atripla – Europe

2

5

10

17

Atripla – Other International

4

9

12

19

27

113

118

311

Complera / Eviplera – U.S.

28

26

73

77

Complera / Eviplera – Europe

31

35

104

124

Complera / Eviplera – Other International

5

9

12

17

64

70

189

218

Stribild – U.S.

28

27

94

100

Stribild – Europe

11

13

33

42

Stribild – Other International

3

2

12

12

42

42

139

154

Truvada – U.S.

55

492

268

1,245

Truvada – Europe

5

6

18

20

Truvada – Other International

7

11

24

37

67

509

310

1,302

Total Truvada (FTC/TDF) Based Products – U.S.

132

644

531

1,697

Total Truvada (FTC/TDF) Based Products – Europe

49

59

165

203

Total Truvada (FTC/TDF) Based Products – Other International

19

31

60

85

200

734

756

1,985

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2021

2020

2021

2020

Other HIV (2) – U.S.

3

10

14

24

Other HIV (2) – Europe

4

1

9

4

Other HIV (2) – Other International

2

12

21

7

13

35

49

Total HIV – U.S.

3,302

3,722

9,132

10,213

Total HIV – Europe

602

569

1,776

1,720

Total HIV – Other International

285

256

869

748

4,189

4,547

11,777

12,681

HCV Products

Ledipasvir / Sofosbuvir (3) – U.S.

14

36

63

113

Ledipasvir / Sofosbuvir (3) – Europe

5

11

24

26

Ledipasvir / Sofosbuvir (3) – Other International

26

37

76

124

45

84

163

263

Sofosbuvir / Velpatasvir (4) – U.S.

173

170

649

646

Sofosbuvir / Velpatasvir (4) – Europe

77

74

234

253

Sofosbuvir / Velpatasvir (4) – Other International

82

86

272

330

332

330

1,155

1,229

Other HCV (5) – U.S.

37

35

97

100

Other HCV (5) – Europe

12

13

64

37

Other HCV (5) – Other International

3

2

9

12

52

50

170

149

Total HCV – U.S.

224

241

809

859

Total HCV – Europe

94

98

322

316

Total HCV – Other International

111

125

357

466

429

464

1,488

1,641

HBV/HDV Products

Vemlidy – U.S.

103

99

266

248

Vemlidy – Europe

9

8

25

22

Vemlidy – Other International

96

70

298

194

208

177

589

464

Viread – U.S.

1

3

8

10

Viread – Europe

7

8

22

27

Viread – Other International

18

21

55

100

26

32

85

137

Other HBV/HDV (6) – U.S.

1

9

Other HBV/HDV (6) – Europe

13

2

29

6

13

2

30

15

Total HBV/HDV – U.S.

104

102

275

267

Total HBV/HDV – Europe

29

18

76

55

Total HBV/HDV – Other International

114

91

353

294

247

211

704

616

Veklury

Veklury – U.S.

1,527

785

2,763

785

Veklury – Europe

109

60

761

60

Veklury – Other International

287

28

684

28

1,923

873

4,208

873

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2021

2020

2021

2020

Cell Therapy Products

Tecartus – U.S.

35

5

94

5

Tecartus – Europe

12

4

25

5

47

9

119

10

Yescarta – U.S.

100

85

300

283

Yescarta – Europe

66

51

188

144

Yescarta – Other International

9

2

25

7

175

138

513

434

Total Cell Therapy – U.S.

135

90

394

288

Total Cell Therapy – Europe

78

55

213

149

Total Cell Therapy – Other International

9

2

25

7

222

147

632

444

Trodelvy

Trodelvy – U.S.

100

261

Trodelvy– Europe

1

1

101

262

Other Products

AmBisome – U.S.

7

18

32

46

AmBisome – Europe

67

58

202

166

AmBisome – Other International

69

35

186

113

143

111

420

325

Letairis – U.S.

46

78

157

241

Ranexa – U.S.

5

9

Zydelig – U.S.

6

8

22

24

Zydelig – Europe

7

9

27

30

Zydelig – Other International

1

1

13

17

50

55

Other (7) – U.S.

28

32

82

103

Other (7) – Europe

10

10

41

32

Other (7) – Other International

5

3

22

7

43

45

145

142

Total Other – U.S.

87

136

298

423

Total Other – Europe

84

77

270

228

Total Other – Other International

74

38

209

121

245

251

777

772

Total product sales – U.S.

5,479

5,076

13,932

12,835

Total product sales – Europe

997

877

3,419

2,528

Total product sales – Other International

880

540

2,497

1,664

$

7,356

$

6,493

$

19,848

$

17,027

_______________________________

(1) Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2) Includes Emtriva and Tybost.

(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

(5) Includes Vosevi and Sovaldi.

(6) Includes Hepcludex and Hepsera. The nine months ended September 30, 2021 includes $25 million of Hepcludex sales recorded subsequent to Gilead's acquisition of MYR.

(7) Includes Cayston and Jyseleca.

Investors:
Jacquie Ross, CFA
(650) 358-1054

Media:
Chris Ridley
(908) 883-0478

News Provided by Business Wire via QuoteMedia

CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Upcoming Lead Plaintiff Deadline

The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE:ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

TO VIEW OUR COMPLAINT, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: JUNE 6, 2022

CLASS PERIOD: APRIL 30, 2021 through AUGUST 31, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:

James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

ABBVIE'S ALLEGED MISCONDUCT

AbbVie is one of the world's largest pharmaceutical companies. The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales. Rinvoq-an anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes-was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (FDA) to approve Rinvoq for the treatment of several other diseases.

As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz's risk of triggering certain serious side effects. Beginning in February 2019, the FDA repeatedly warned the public that the safety trial indicated that Xeljanz's use could lead to serious heart-related issue, cancer, and other adverse events. Notwithstanding the similarities between Rinvoq and Xeljanz, during the Class Period, Defendants assured investors that Rinvoq was far safer than Xeljanz and not subject to the same regulatory risks.

However, investors began to learn the truth about Rinvoq's significant risks on June 25, 2021, when AbbVie revealed that the FDA was delaying its review of expanded treatment applications for Rinvoq due to the safety concerns associated with Xeljanz. On this news, the price of AbbVie common stock declined $1.76 per share, or approximately 1.5%, from a close of $114.74 per share on June 24, 2021, to close at $112.98 per share on June 25, 2021.

Then, on September 1, 2021, the FDA announced that final results from the Xeljanz safety trial established an increased risk of serious adverse events, even with low doses of Xeljanz. As a result, the FDA determined that it would require new and updated warnings for Xeljanz and Rinvoq because Rinvoq "share[s] similar mechanisms of action with Xeljanz" and "may have similar risks as seen in the Xeljanz safety trial." The FDA also indicated that it would further limit approved indications for Rinvoq as a result of these safety concerns. On this news, the price of AbbVie common stock declined $8.51 per share, or more than 7%, from a close of $120.78 per share on August 31, 2021, to close at $112.27 per share on September 1, 2021.

After the Class Period, on December 3, 2021, AbbVie announced that the FDA had updated Rinvoq's label to require additional safety warnings and limit marketing of Rinvoq to only its use after treatment with other drugs has failed. On January 11, 2022, Defendants admitted that these changes to Rinvoq's label would negatively impact sales, forcing the Company to reduce its long-term guidance for Rinvoq's sales in 2025.

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

WHAT CAN I DO?

AbbVieinvestors may, no later than June 6, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLPor other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages AbbVie investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP



View source version on accesswire.com:
https://www.accesswire.com/702143/CLASS-ACTION-ALERT-Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc-Investors-of-Upcoming-Lead-Plaintiff-Deadline

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: ABBV NTRA MULN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

AbbVie Inc. (NYSE:ABBV)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=27532&wire=1
Lead Plaintiff Deadline: June 6, 2022
Class Period: April 30, 2021 - August 31, 2021

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

SHAREHOLDER ALERT: AUPH LILM AXSM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association Congress

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals

In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Lawsuits Filed Against ABBV, RSKD and ARQQ - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

ABBVie Inc. (NYSE:ABBV)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AUPH, LILM and LICY

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Class Period: May 7, 2021 - February 25, 2022
Lead Plaintiff Deadline: June 14, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×